Regulations.gov document
Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the…
Notice · FDA-2009-D-0283 · posted Oct 25, 2019
Key facts
| Document ID | FDA-2009-D-0283-0022 |
|---|---|
| Title | Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act; Draft Guidance for Industry; Availability |
| Document type | Notice |
| Subtype | Notice of Availability |
| Agency | FDA |
| Docket | FDA-2009-D-0283 |
| Posted | Oct 25, 2019 |
| Federal Register citation | 84 FR 57452 |
| FR document number | 2019-23312 |
| Comment period opens | Oct 25, 2019 |
| Comments due | Dec 25, 2019 |
| Effective date | Oct 25, 2019 |
At a glance
- 1–9 Pages
- No Open for comment
- 10–99 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: